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Transcriptional coregulatorThe oncogenic corepressors C-terminal Binding Protein (CtBP) 1 and 2 harbor regulatory D-isomer
speciﬁc 2-hydroxyacid dehydrogenase (D2-HDH) domains. 4-Methylthio 2-oxobutyric acid (MTOB)
exhibits substrate inhibition and can interfere with CtBP oncogenic activity in cell culture and mice.
Crystal structures of human CtBP1 and CtBP2 in complex with MTOB and NAD+ revealed two key fea-
tures: a conserved tryptophan that likely contributes to substrate speciﬁcity and a hydrophilic cavity
that links MTOB with an NAD+ phosphate. Neither feature is present in other D2-HDH enzymes. These
structures thus offer key opportunities for the development of highly selective anti-neoplastic CtBP
inhibitors.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction (D-HicDH) and, importantly for the development of inhibitors spe-The paralogous transcription coregulators C-terminal Binding
Proteins (CtBP) 1 and 2 are critical modulators of numerous cellu-
lar processes; overexpression of both has been linked to multiple
human cancers. CtBP1 was initially identiﬁed due to its interaction
with the C-terminal region of the adenovirus E1A oncoprotein and
modulation of E1A transforming activities [1,2]. CtBP functions as a
transcriptional regulator by tethering chromatin remodeling pro-
teins, such as histone deacetylases, histone methyl transferases,
and histone demethylases, to DNA bound transcription factors
[3,4]. Alternative splice forms of CtBP1 and 2 also have non-nuclear
functions in the Golgi and at synapses [5]. CtBP1 and 2 are unique
among transcription factors in the incorporation of a D-isomer spe-
ciﬁc 2-hydroxyacid dehydrogenase (D2-HDH) domain, which re-
duces or oxidizes substrates utilizing coenzyme NAD(P)+/
NAD(P)H [6]. The D2-HDH family (Fig. S1), which is not otherwise
involved in transcriptional regulation, includes bacterial D-lactate
dehydrogenase (D-LDH) and D-hydroxyisocaproate dehydrogenaseciﬁc for human CtBP, the human enzymes glyoxylate reductase/
hydroxypyruvate reductase (GRHPR) and phosphoglycerate dehy-
drogenase (PHGDH) [7–10]. CtBP recruitment of coenzyme nicotin-
amide adenine dinucleotide (NAD+) or NADH induces dimerization
[11], an event necessary for transcriptional repressor activity, link-
ing enzymatic function and transcriptional activity [12]. With a re-
ported 100 fold higher afﬁnity for NADH than NAD+ [13], CtBP may
be able to respond to the redox state of the cell, increasing repres-
sor function when stimuli, such as hypoxia and high extracellular
glucose levels, increase the NADH/NAD+ ratio [14,15].
Mounting evidence implicates CtBP repressor function in hu-
man cancer. CtBP corepression activity targets pro-apoptotic fac-
tors (Bik, Noxa), cytoskeletal/cell adhesion molecules (keratin-8,
E-cadherin) [16], and tumor suppressors (p16INK4a, p15INK4b) [4],
facilitating the epithelial to mesenchymal transition (EMT), confer-
ring resistance to apoptosis and promoting metastasis and onco-
genesis [17]. CtBP is targeted for degradation by individual or
combined effects of multiple tumor suppressors including ade-
nomatous polyposis coli (APC) [18,19], homeodomain-interacting
protein kinase 2 (HIPK2) [20], JNK1 [21], and alternative reading
frame (ARF) [22]. Consistent with these cellular effects of CtBP,
overexpression of CtBP is observed in the majority of human colon,
prostate, ovarian, and breast cancers [23–27].
A substrate for CtBP catalysis, 4-Methylthio 2-oxobutyric acid
(MTOB) antagonizes CtBP transcriptional regulation [23,27,28].
MTOB induced apoptosis through displacement of CtBP2 from
Table 1
Data collection and reﬁnement statistics.
Data collection CtBP1–MTOB CtBP2–MTOB
Wavelength (Å) 0.99 0.99
Resolution range (Å)a 29.92–2.38 (2.47–
2.38)
32.30–2.86 (2.96–
2.86)
Space group P6422 P21
Unit cell
a, b, c (Å) 88.97, 88.97, 161.54 86.15, 140.61, 135.13
a, b, c () 90, 90, 120 90, 97.87, 90
Total reﬂections 167249 298092
Unique reﬂections 15538 73354
Multiplicity⁄ 10.7 (11.6) 4.1 (4.0)
Completeness (%)⁄ 97.9 (99.9) 99.3 (96.9)
Mean I/sigma (I)⁄ 22.7 (7.1) 9.6 (3.3)
Wilson B-factor 52.8 54.3
R-sym (%)⁄ 6.5 (39.0) 9.3 (38.9)
Reﬁnement
R-factor (%)⁄ 20.0 (27.7) 21.4 (30.1)
R-free (%)⁄ 23.9 (38.9) 25.1 (33.3)
Number of atoms 2644 20058
Protein 2463 19429
1744 B.J. Hilbert et al. / FEBS Letters 588 (2014) 1743–1748the Bik promoter in HCT116 colon cancer cells [23]. Administering
MTOB in mouse xenograft models resulted in decreased tumor
burden and prolonged survival for MTOB treated mice compared
with untreated mice [23]. Additionally, MTOB evicted CtBP from
target promoters in breast cancer cell lines, shifting phenotypic
indicators (E-cadherin/vimentin) from mesenchymal to a more
epithelial phenotype [27]. Although high MTOB concentrations
(mM) are required for (substrate) inhibition of CtBP, MTOB’s clear
inhibitory effect on cancer cells provides proof of principle that
small molecules could be developed to effectively treat cancers
speciﬁcally regulated by CtBP activity.
Crystal structures of both CtBP1 and 2 have been reported
[29–31], but none are in complex with potential substrates. We
report here crystal structures for both human CtBP1 (28–353)
and CtBP2 (33–364) minimal dehydrogenase domains in ternary
complexes with coenzyme NAD+ and ligand MTOB. These struc-
tures reveal unique active site CtBP features, including a prominent
tryptophan and a hydrophilic channel, which may be useful for the
design of highly selective inhibitors.Ligands 97 424
Water molecules 84 205
Protein residues 327 2646
RMS (bonds) 0.009 0.009
RMS (angles) 1.27 1.15
Ramachandran favored
(%)
96 96
Ramachandran outliers
(%)
0 0
Clashscore 3.79 11.14
Average B-factor 55.5 52.7
Protein average B-factor 55.9 52.9
Water average B-factor 53.5 44.3
a Highest resolution shell shown in parentheses.2. Materials and methods
2.1. Protein expression and puriﬁcation
As described more fully in the Supplementary material, both
CtBP1 and 2 were expressed as His6-tagged proteins in BL21-
CodonPlus(DE3)-RIL competent cells (Stratagene). Both proteins
were puriﬁed using NiNTA beads (Qiagen) followed by size-exclu-
sion on a Superdex 75 column. The His6 tag was cleaved from
CtBP2 with Thrombin (Novagen) prior to the size exclusion step,
but was not cleaved from CtBP1.Fig. 1. Binding of MTOB to CtBP. (a) CtBP1 monomer domains; the substrate
binding domain (orange) and coenzyme binding domain (green) are connected
through a hinge (grey). MTOB (cyan) and NAD+ bind in an active site cleft formed at
the interface of the domains. The interface between subunits of the physiological
dimer is primarily formed between the coenzyme binding domain, including
extensive contacts formed by the dimerization loop. (b) and (c) The 2FoFc maps for
MTOB in CtBP1 (1r; 0.20 e-/Å3) and CtBP2 monomer A (1r; 0.27 e-/Å3), respec-
tively. MTOB atom labels are shown in CtBP1 (b).2.2. Crystallization of ternary CtBP2/NAD+/MTOB complex
Protein (20–25 mg/ml) incubated with a 50 M excess of MTOB
overnight at 4 C was mixed in a 2:1 ratio with buffer and crystal-
lized by hanging drop vapor diffusion in 24 well VDX plates. The
highest quality crystals were grown in buffer containing 200 mM,
potassium nitrate, 15–20% PEG 3350, and 100 mM bis tris propane
pH 7.0. Crystals typically grew as multiple joined plates; microsee-
ding resulted in large single plates suitable for diffraction. Crystals
were cryoprotected by submersion in mother liquor supplemented
with 20% ethylene glycol for 5–10 s and then ﬂash frozen in liquid
nitrogen.
2.3. Crystallization of ternary CtBP1/NAD+/MTOB complex
Protein (10 mg/ml) was mixed with a 50 M excess of MTOB
immediately before hanging drops were setup. Bipyramidal crys-
tals grew overnight at room temperature in 200–300 mM magne-
sium chloride, 0–140 mM sodium formate, 100 mM HEPES pH
7.5, and 2.5 mM NAD+. Crystals were cryoprotected by adding well
buffer solution supplemented with increasing amounts of glycerol.
Once the drop containing the crystal reached 20% v/v glycerol, the
crystal was moved to 30% glycerol for 5 s and ﬂash frozen in liquid
nitrogen.
2.4. Data collection and structure solution
Diffraction data for the CtBP1/NAD+/MTOB and CtBP2/NAD+/
MTOB complexes were collected on the BioCARS 14-BM-C beam-
line at the Advanced Photon Source of Argonne National Labora-
tory. The initial models were obtained by molecular replacement
with PhaserMR [32]. For CtBP1, the binary complex (1MX3 [29])
was used as a search model, whereas for CtBP2, individual cofactorand substrate binding domains of the binary CtBP2 complex
(2OME) were used as described in the Supplementary material.
Water molecules were automatically generated by Arp/Warp
[33], and the structure was reﬁned with RefMac5 [34]. All other
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tween rounds of reﬁnement was performed with Coot [36]. The
atomic coordinates and structure factor amplitudes of CtBP1 and
CtBP2 with bound MTOB and NAD+ have been deposited in the
RCSB Protein Data Bank, www.rcsb.org, with accession numbers
4LCE and 4LCJ, respectively.
3. Results and discussion
3.1. Overall CtBP/MTOB/NAD+ structures
As with previous binary crystal structures, CtBP1 crystallized
with a single monomer per asymmetric unit and the molecular
dyad of the physiological dimer (Fig. S2) coincident with a twofold
crystallographic axis of space group P6422. The CtBP2 asymmetric
unit contains eight monomers, arranged as four dimeric pairs. For
full crystallographic statistics, see Table 1.
MTOB binds into an active site cleft between the discontinuous
substrate binding domain (28–120; 327–353) and coenzyme bind-
ing domain (125–319) (Fig. 1a). Alignment with previous binary
structures and distance difference matrix plots (SupplementaryFig. 2. MTOB interactions in CtBP active site shown in stereo. (a) and (b) MTOB conserv
monomer A, respectively. An additional bond (not shown) exists between MTOB O5 a
monomers. (c) MTOB conformation differs between CtBP1 and CtBP2. In CtBP1 (cyan) th
CtBP2 MTOB lacks an extensive interaction as R103 positions further away. The sulfur ato
pi interaction that appears to confer MTOB speciﬁcity.data) reveal only minor differences in Ca positions upon MTOB
binding to both CtBP1 and CtBP2, with rms deviations of
0.2–0.3 Å for monomer superpositions and 0.2–0.4 Å for dimer
superpositions. Thus, MTOB does not induce overall tertiary or
quaternary change. These results argue against ligand-linked
conformational changes as driving transcriptional modulation.
One possibility is that substrate turnover, generating NAD+ whose
release may drive dimer dissociation, might underlie the transcrip-
tional inhibition of CtBP by MTOB. An additional possibility is that,
conversely, inhibition of NADH to NAD+ conversion at high MTOB
concentrations (via substrate inhibition) may block transcriptional
activities that could require cycling between dimer and monomer
forms that would be expected at physiologic MTOB and NADH/
NAD+ concentrations.
3.2. Stereochemistry of MTOB binding
MTOB is positioned in the active site similarly to ligands in
other members of the D2-HDH protein family of proteins
[7,10,37]. MTOB binds between an active site loop from the sub-
strate binding domain and catalytically conserved residues Arged hydrogen bonds (orange) and unique hydrogen bonds (blue) in CtBP1 and CtBP2
nd R272 NH2 in CtBP2 monomer A. This bond is not conserved across all CtBP2
e MTOB carboxylate twists relative to CtBP2 (dark blue) to form contacts with R97.
ms of MTOB in both structures position about 4 Å fromW318/324, forming a sulfur–
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positioned adjacent to the NAD+ nicotinamide ring (Fig. 1). Thus,
the position is consistent with MTOB as a potential substrate that
can be reduced by NADH.
Given the resolution of the crystallographic data (CtBP1 2.38 Å,
CtBP2 2.86 Å), particular care was taken in modeling MTOB (Sup-
plementary material). Electron density clearly allows placement
of MTOB, with highest density levels at the MTOB sulfur (S8) and
along the C2–C4 bond (see Fig. 1b for atom designations) in the
a-keto acid moiety.
In both CtBP1 and CtBP2, the FoFc maps and reﬁned B-factors
indicate that MTOB does not occupy all active sites in the crystal.
For CtBP1, best crystallographic results were obtained with an
occupancy of 67% (Supplementary material). For CtBP2, the quality
of the 2FoFc density varies across the eight monomers, ranging
from excellent to poor, but in all monomers, density was present
for the MTOB sulfur atom (S8) and at least some of the a-keto acid
moiety (Supplementary data). Omit FoFc density maps conﬁrm
correct MTOB placement in CtBP2, yielding high conﬁdence of
MTOB conformation in monomers A, C and H. The occupancies of
MTOB were reﬁned in PHENIX to 79% in monomers A and C, and
these were utilized for analysis of binding stereochemistry.
MTOB forms favorable hydrogen bonds in the CtBP active site
similar to those observed for substrate binding in other D2-HDHs
(Table S1). The MTOB pyruvate moiety hydrogen bonding in CtBP2
more closely matches other D2-HDHs than it does in CtBP1, due to
an unusual twist of the MTOB carboxylate in CtBP1 (Fig. 2). The cat-
alytically conserved Arg266 (CtBP1)/272(CtBP2) and His315/321
from the coenzyme binding domain provide two hydrogen bondsFig. 3. Ordered water molecules in CtBP hydrophilic active site cavity. (a) Four water m
NAD+ phosphate. (b) In addition to the MTOB bound structure (red), other CtBP1 struct
Position of W1 varies depending on the occupants of the active site. W2–W4 display le
additional water (labeled with a white ‘‘x’’) suggest high mobility. (c) Individual monom
purple; monomer F, orange; monomer G, green). (d) The FoFc map (0.24 e-/Å3) of MT
monomer G (purple), and monomer H (blue). MTOB (dark blue) clashes with the W1 (rin CtBP1 and three hydrogen bonds in CtBP2. The backbone amides
in a ﬂexible loop in the substrate-binding domain provide twomore
hydrogen bond donors, helping bridge the active site cleft. In CtBP1,
Arg97 reaches deeper into the active site than the homologous
Arg103 of CtBP2, donating a unique hydrogen bond and increased
coulombic interaction to the MTOB carboxylate. Therefore, a
network of four fully conserved hydrogen bonds, with additional
variable hydrogen bonds, anchors MTOB in the active sites in CtBP1
and CtBP2.
Analysis of van der Waals interactions between MTOB and CtBP
(Fig. S10) reveals that the MTOB a-keto group contacts CtBP simi-
larly to substrates in other liganded D2-DHDs. A striking difference,
however, is the presence of smaller side-chains at positions
Ala123/129 and Ser123/Ala130 in CtBP compared with bulky resi-
dues at homologous positions in other D2-DHDs that contact sub-
strate (Fig. S1, blue asterisks). Outside the a-keto moiety, MTOB
contacts include mostly residues previously implicated in sub-
strate speciﬁcity of other D2-DHDs, including CtBP residues
Tyr76/82, His77/83, and Met327/333, as well as Val1590/1650 from
the neighboring dimeric subunit. The packing of these residues
would be predicted to prevent a-keto acids larger than MTOB from
binding.
3.3. Unique active site properties
Unlike other D2-HDH enzymes, a Trp(318/324) dominates the
active site in CtBP and is within van der Waals distance of all MTOB
atoms outside the a-keto acid moiety (Fig. 2). This Trp has recently
been implicated both as a dimerization switch in CtBP1 [38] and inolecules in CtBP1, W1–W4, form a network unique to CtBP from MTOB (cyan) to an
ures (1MX3, blue; 1HKU, green; 2HU2, yellow) possess a nearly identical network.
ss variation. Human CtBP1 (1MX3) possesses ﬁve waters, although B-factors of the
ers of the unbound CtBP2 structure (2OME) also possess the waters (monomer C,
OB bound CtBP2 suggests the presence of waters W2–W4 in monomer A (green),
ed disks) when aligned to the CtBP1 structure.
Fig. 4. Uniqueness of CtBP active site cavity. (a) MTOB (cyan) and the water
network ﬁll the CtBP1 (grey) active site cavity (blue surface). Small residue S124
(CtBP2 A130) does not contact MTOB or the active site loop, leaving a gap that
allows the water network to form. (b) and (c) Related human proteins do not
possess the full water network. The active site cavities for GRHPR (2WWR – green
surface) and PHGDH (2G76 – purple surface) are restricted to the volume adjacent
to the catalytic residues. GRHPR L107 contacts the active site loop and enzymatic
product, D-glycerate. PHGDH N106 also contacts the active site loop and a malate
ion, which sits in the substrate binding site. These larger residues close the gap
around the substrate/product pocket, leaving room only for waters to bind near the
coenzyme phosphate group.
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ADP ribosyl conjugate of rat CtBP1/BARS [39]. Interestingly, the
MTOB S8 atom centers over the CtBP Trp318/324 indole, rather than
orienting its lone pair of electrons towards the positively charged
CtBP Arg97/103, suggesting a sulfur–p interaction [40,41]. The ﬁnd-
ing that replacing the MTOB sulfur with a methylene carbon
decreased enzymatic efﬁciency 8 fold [28], indicates that this
sulfur–p interaction contributes to the substrate speciﬁcity of CtBP.
Trp318/324 provides an extensive active site surface that represents
an opportunity for inhibitor design as it is a characteristic not shared
by other D2-DHD family members (Fig. S1, green diamond).
A second unique aspect of the CtBP active site is a hydrophilic
cavity between the MTOB binding site and NAD+. Four ordered
water molecules, designated W1 through W4, ﬁll this cavity in
the CtBP1 ternary structure and link MTOB through hydrogen
bonds with the phosphate group of NAD+ (Fig. 3a). W1 forms a
hydrogen bond directly with MTOB O3 and W4 forms a hydrogen
bond with the NAD+ phosphate. Two other CtBP1 structures, the
human CtBP1 binary complex [29] (pdb code 1MX3) and a rat
CtBP1 binary complex [30] (pdb code 1HKU), display water mole-
cules at these four positions, while a lower resolution rat CtBP1
[31] (pdb code 2HU2) retains only water molecules at the W1
and W2 sites (Fig. 3b). Individual monomers in the binary CtBP2
structure (pdb 2OME) contain some of the conserved waters de-
spite the low resolution relative to the CtBP1 structures (Fig. 3c).
Although the low resolution of the CtBP2–MTOB complex prevents
conﬁdent modeling, the FoFc map in our CtBP2 structure shows
positive density at some positions of the water network (Fig. 3d).
The locations of the water molecules that ﬁll the active site cav-
ity are very similar, with the exception of position W1 (Fig. 3b and
c). The precise binding location for this water molecule depends
upon the occupants of the active site in various structures, with
binding of ions (acetate or formate), MTOB or other water mole-
cules dictating the location of water binding. Interestingly, the
CtBP2 MTOB carboxylate sterically clashes with a water at position
W1, which may account for the lack of positive FoFc density at
this position (Fig. 3d). Most likely the CtBP1 MTOB carboxylate
shift towards Arg97 is required for a water molecule to bind at po-
sition W1 in the CtBP1 ternary structure. Water molecules W2, W3
and W4 show less positional variation (Fig. 3b).
The observed active site cavity is present because CtBP lacks a
bulky residue that is involved in substrate binding in other
D2-HDHs. In these other family members, a residue with a large
side chain typically occupies the homologous position to CtBP1
Ala123 or Ser124 (CtBP2 Ala129 or Ala130) in the hinge region just
outside the coenzyme binding domain (Fig. S1, blue asterisks).
These side chains interact with and stabilize substrate in both bac-
terial and human D2-HDHs. A tyrosine residue occupies the A123
position in three bacterial structures [9,10,37]. In the human D2-
HDHs PHGDH and GRHPR, similar bulky residues contact the sub-
strate. Leu107 of GRHPR substitutes for CtBP1 S124, providing van
der Waals contacts to the carboxylate of the enzymatic product,
D-Glycerate [7]. In PHGDH, Asn106 substitutes for CtBP1 S124,
interacting with a bound malate carboxylate [8]. These bulky side
chains that ﬁll the hydrophilic channel in other D2-HDH’s prevent
binding of the ordered water molecules that are observed in our
CtBP structures (Fig. 4). Therefore, the cavity containing the
observed water network in CtBP is a unique characteristic that
may be exploited in future drug design to maximize speciﬁcity
for CtBP inhibition vs. other D2-HDH family members that play
important roles in cellular metabolism.
The goals of our ternary MTOB/NAD+/CtBP structure determina-
tion were to obtain insights into the mechanism of inhibition and
to determine detailed interactions that may facilitate inhibitor de-
sign. Given the lack of structural changes upon MTOB binding,
mechanisms other than quaternary and tertiary rearrangementslikely underlie inhibition. Based on the detailed understanding of
the unusual CtBP active site cleft provided by the CtBP1/2-MTOB
structures, including a prominent Trp and water channel, highly
potent and speciﬁc bifunctional inhibitors can be envisioned that
bind not only in the MTOB binding site and adjoining cavity, but
also connect to moieties of the NAD(H) binding site. As a result,
we are currently exploring compounds with aromatic character
to strengthen interactions with Trp 318/324 and intend to investi-
gate compounds capable of interfering with NADH mediated
dimerization. Thus, these results provide a basis for the design of
highly speciﬁc inhibitors of CtBP that could lead to therapeutically
valuable compounds.
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